A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)
Sven J. van der Lee (Vrije Universiteit Amsterdam)
Erik van den Akker (TU Delft - Electrical Engineering, Mathematics and Computer Science, Leiden University Medical Center)
Najada Stringa (Amsterdam UMC)
Marc Hulsman (TU Delft - Electrical Engineering, Mathematics and Computer Science, Vrije Universiteit Amsterdam)
Niccolo Tesi (TU Delft - Electrical Engineering, Mathematics and Computer Science, Vrije Universiteit Amsterdam)
P. Alexopoulos
G. Rossi
J. van der Zee
Marcel J.T. Reinders (Delft Bioinformatics Lab, TU Delft - Electrical Engineering, Mathematics and Computer Science)
undefined More Authors (External organisation)
More Info
expand_more
Abstract
The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.